Harrington D S, Patil K, Lai P K, Yasuda N N, Armitage J O, Ip S H, Weisenburger D D, Linder J, Purtilo D T
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha 68105.
Arch Pathol Lab Med. 1988 Jun;112(6):597-601.
We performed a retrospective analysis of serum interleukin 2 receptor (IL-2R) levels in a group of 35 patients with malignant lymphoma (ML; 13 T cell and 22 B cell) using a new enzyme immunoassay. Our objectives were to determine if elevated levels of soluble IL-2R occur in patients with active ML, whether serum IL-2R levels are prognostic, and whether prospective studies are warranted. Our preliminary data indicate that serum IL-2R levels correlate with disease activity and size of tumor, but not with grade or stage of the tumor. Five-year actuarial survival was 20% for patients with IL-2R levels greater than 1000 U/mL at any time during their course and 86% for patients who did not exceed that threshold. Furthermore, patients with IL-2R levels lower than 1000 U/mL were more likely to achieve a complete remission. Serum lactate dehydrogenase and uric acid levels did not show significant correlation with disease activity or prognosis. We conclude that serum IL-2R levels may have clinical and prognostic significance in patients with ML and that prospective studies are indicated.
我们使用一种新的酶免疫测定法，对一组35例恶性淋巴瘤（ML；13例T细胞淋巴瘤和22例B细胞淋巴瘤）患者的血清白细胞介素2受体（IL-2R）水平进行了回顾性分析。我们的目的是确定活动性ML患者中可溶性IL-2R水平是否升高，血清IL-2R水平是否具有预后价值，以及是否有必要进行前瞻性研究。我们的初步数据表明，血清IL-2R水平与疾病活动度和肿瘤大小相关，但与肿瘤分级或分期无关。在病程中任何时间IL-2R水平大于1000 U/mL的患者，其5年精算生存率为20%，未超过该阈值的患者为86%。此外，IL-2R水平低于1000 U/mL的患者更有可能实现完全缓解。血清乳酸脱氢酶和尿酸水平与疾病活动度或预后无显著相关性。我们得出结论，血清IL-2R水平可能对ML患者具有临床和预后意义，因此有必要进行前瞻性研究。
